Cargando…
Danicopan, an Oral Complement Factor D Inhibitor, Exhibits High and Sustained Exposure in Ocular Tissues in Preclinical Studies
PURPOSE: Complement alternative pathway (AP) dysregulation has been implicated in geographic atrophy, an advanced form of age-related macular degeneration. Danicopan is an investigational, first-in-class inhibitor of factor D, an essential AP activation enzyme. We assessed danicopan distribution to...
Autores principales: | Boyer, David D., Ko, Ya-Ping, Podos, Steven D., Cartwright, Mark E., Gao, Xiang, Wiles, Jason A., Huang, Mingjun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Association for Research in Vision and Ophthalmology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624268/ https://www.ncbi.nlm.nih.gov/pubmed/36301553 http://dx.doi.org/10.1167/tvst.11.10.37 |
Ejemplares similares
-
Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria
por: Risitano, Antonio M., et al.
Publicado: (2020) -
Sustained Ocular Delivery of Bevacizumab Using Densomeres in Rabbits: Effects on Molecular Integrity and Bioactivity
por: Peterson, Jan S., et al.
Publicado: (2023) -
AAV Gene Augmentation of Truncated Complement Factor H Differentially Rescues Ocular Complement Dysregulation in a Mouse Model
por: Grigsby, Daniel, et al.
Publicado: (2023) -
Complement Activation in the Vitreous of Patients With Proliferative Diabetic Retinopathy
por: Mandava, Nikhil, et al.
Publicado: (2020) -
Complement Activation Levels Are Related to Disease Stage in AMD
por: Heesterbeek, Thomas J., et al.
Publicado: (2020)